Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Entacapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT known ✓ | P21964 | 5/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entacapone SCHEMBL3395296 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL34505 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL29356206 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL3934631 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL29406523 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL27766815 | 0.99 | FTO (0.98) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL4940150 | 0.98 | FTO (0.96) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL4940155 | 0.98 | FTO (0.96) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL26128138 | 0.97 | FTO (0.94) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL3972337 | 0.96 | FTO (0.92) | FTOCOMTMEN1KMT2AABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18835 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026106939-A1 | IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260130881-A1 | SUSTAINED RELEASE DEVICE CONTENTS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER DISORDERS | BUSHARA KHALAFALLA (US) | 2026-05-14 | — | — | US | claimed |
| US-20260131140-A1 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIV (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739298-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| WO-1998031355-A2 | PHARMACEUTICAL COMPOSITION COMPRISING N-PROPYLNORAPOMORPHINE AND CATHECOL-O-METHYL-TRANSFERASE INHIBITOR FOR TREATING PARKINSON'S DISEASE | BRITANNIA PHARMACEUTICALS LIMITED (GB) | 1998-07-23 | — | — | WO | claimed |
| EP-0444899-B1 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION YHTYMAE OY (FI) | 1997-02-05 | — | — | EP | claimed |
| EP-0537742-B1 | Styrene derivatives | MITSUBISHI CHEM CORP (JP) | 1996-08-21 | — | — | EP | claimed |
| EP-0426468-B1 | Stabile polymorphic form of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide and the process for its preparation | ORION YHTYMAE OY (FI) | 1995-09-06 | — | — | EP | claimed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | claimed |
| US-5135950-A | Crystallized from lower aliphatic carboxylic acid with hydrochloric or hydrobromic acid catalyst | ORION-YHTYMA OY (FI) | 1992-08-04 | — | — | US | claimed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | claimed |
| EP-0444899-A2 | Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation | ORION-YHTYMÀ OY (FI) | 1991-09-04 | — | — | EP | claimed |
| EP-0426468-A2 | Stabile polymorphic form of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide and the process for its preparation | ORION-YHTYMÄ OY (FI) | 1991-05-08 | — | — | EP | claimed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | claimed |